On May 9, 2024, Eli Lilly and Company announced that it held its annual general meeting of shareholders on May 6, 2024, and declared voting results. Accordingly, a shareholder proposal from Trinity Health, requesting to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents was not approved.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
850 USD | +1.52% | +3.61% | +45.82% |
Jun. 07 | Jefferies Adjusts Price Target on Eli Lilly to $957 From $925 | MT |
Jun. 07 | US FDA Staff Flags Potential Limited Benefit of Eli Lilly's Alzheimer's Disease Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.87% | 248B | |
-1.23% | 219B | |
+11.16% | 216B | |
+5.90% | 164B | |
-0.73% | 162B | |
-0.52% | 123B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Declaration of Voting Results by Eli Lilly and Company